167 related articles for article (PubMed ID: 8955200)
1. A nine-amino acid peptide from IL-1beta augments antitumor immune responses induced by protein and DNA vaccines.
Hakim I; Levy S; Levy R
J Immunol; 1996 Dec; 157(12):5503-11. PubMed ID: 8955200
[TBL] [Abstract][Full Text] [Related]
2. Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor.
Chen TT; Tao MH; Levy R
J Immunol; 1994 Nov; 153(10):4775-87. PubMed ID: 7525715
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
[TBL] [Abstract][Full Text] [Related]
4. Rapid expression of vaccine proteins for B-cell lymphoma in a cell-free system.
Yang J; Kanter G; Voloshin A; Michel-Reydellet N; Velkeen H; Levy R; Swartz JR
Biotechnol Bioeng; 2005 Mar; 89(5):503-11. PubMed ID: 15669088
[TBL] [Abstract][Full Text] [Related]
5. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma.
Tao MH; Levy R
Nature; 1993 Apr; 362(6422):755-8. PubMed ID: 8469286
[TBL] [Abstract][Full Text] [Related]
6. DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells.
Fredriksen AB; Sandlie I; Bogen B
Mol Ther; 2006 Apr; 13(4):776-85. PubMed ID: 16414309
[TBL] [Abstract][Full Text] [Related]
7. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
8. DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C.
Spellerberg MB; Zhu D; Thompsett A; King CA; Hamblin TJ; Stevenson FK
J Immunol; 1997 Aug; 159(4):1885-92. PubMed ID: 9257853
[TBL] [Abstract][Full Text] [Related]
9. DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection.
Syrengelas AD; Levy R
J Immunol; 1999 Apr; 162(8):4790-5. PubMed ID: 10202021
[TBL] [Abstract][Full Text] [Related]
10. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
11. Induction of autoantibody responses to GM-CSF by hyperimmunization with an Id-GM-CSF fusion protein.
Chen TT; Levy R
J Immunol; 1995 Apr; 154(7):3105-17. PubMed ID: 7897201
[TBL] [Abstract][Full Text] [Related]
12. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity.
Levitsky HI; Montgomery J; Ahmadzadeh M; Staveley-O'Carroll K; Guarnieri F; Longo DL; Kwak LW
J Immunol; 1996 May; 156(10):3858-65. PubMed ID: 8621924
[TBL] [Abstract][Full Text] [Related]
13. Anti-lymphoma immunity: relative efficacy of peptide and recombinant DNA vaccine.
Lim SY; Laxmanan S; Stuart G; Ghosh SK
Cancer Detect Prev; 2001; 25(5):470-8. PubMed ID: 11718453
[TBL] [Abstract][Full Text] [Related]
14. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
Stagg J; Wu JH; Bouganim N; Galipeau J
Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
[TBL] [Abstract][Full Text] [Related]
15. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells.
Rinaldi M; Ria F; Parrella P; Signori E; Serra A; Ciafrè SA; Vespignani I; Lazzari M; Farace MG; Saglio G; Fazio VM
Cancer Res; 2001 Feb; 61(4):1555-62. PubMed ID: 11245465
[TBL] [Abstract][Full Text] [Related]
16. A genetic approach to idiotypic vaccination for B cell lymphoma.
Stevenson FK; Zhu D; King CA; Ashworth LJ; Kumar S; Thompsett A; Hawkins RE
Ann N Y Acad Sci; 1995 Nov; 772():212-26. PubMed ID: 8546396
[TBL] [Abstract][Full Text] [Related]
17. Induction of tumor immunity by autologous B lymphoma cells expressing a genetically engineered idiotype.
Selmayr M; Strehl J; Kremer JP; Kremmer E; Doenecke A; Hallek M; Menzel H; Thielemans K; Thierfelder S; Mocikat R
Gene Ther; 1999 May; 6(5):778-84. PubMed ID: 10505101
[TBL] [Abstract][Full Text] [Related]
18. Anti-idiotypic DNA vaccines for lymphoma immunotherapy require the presence of both variable region genes for tumor protection.
Benvenuti F; Burrone OR; Efremov DG
Gene Ther; 2000 Apr; 7(7):605-11. PubMed ID: 10819576
[TBL] [Abstract][Full Text] [Related]
19. Humoral immune responses induced by anti-idiotypic antibody fusion protein of 6B11scFv/hGM-CSF in BALB/c mice.
Chang XH; Ye X; Cui H; Feng J; Li Y; Zhu HL; Yang WL; Fu TY; Cheng HY; Guo HF
Chin Med J (Engl); 2006 Jan; 119(2):131-9. PubMed ID: 16454995
[TBL] [Abstract][Full Text] [Related]
20. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits.
Campbell MJ; Carroll W; Kon S; Thielemans K; Rothbard JB; Levy S; Levy R
J Immunol; 1987 Oct; 139(8):2825-33. PubMed ID: 3498771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
